Inactive Instrument

ImmunoCellular Therapeutics Ltd Nyse

Equities

US4525361055

End-of-day quote Nyse Other stock markets
- ^USD	-

2023	EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in Brazil	CI
2023	EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.	CI

ImmunoCellular Therapeutics : to Present at the BIO CEO & Investor Conference on February 9, 2015

January 28, 2015 at 06:01 am EST

LOS ANGELES, Jan. 28, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the 17(th) Annual BIO CEO & Investor Conference at 2:00 pm ET on Monday, February 9, 2015, at the Waldorf Astoria Hotel in New York City.

http://photos.prnewswire.com/prnvar/20140109/AQ43875LOGO

To access the live audio webcast of the BIO CEO presentation, please log on through a link located in the Investors section of ImmunoCellular's website at www.imuc.com, under the Events & Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles area-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.

Contact:

ImmunoCellular Therapeutics, Ltd.
Jane Green.
Investor Relations
415.348.0010
jane@jmgcomm.com

Logo - http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-to-present-at-the-bio-ceo--investor-conference-on-february-9-2015-300026794.html

SOURCE ImmunoCellular Therapeutics, Ltd.

Latest news about ImmunoCellular Therapeutics Ltd

EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in Brazil	23-09-06	CI
EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.	23-08-02	CI
EOM Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-12-20	CI
ImmunoCellular Therapeutics Ltd. has Changed its Name to EOM Pharmaceuticals Holdings, Inc	22-11-10	CI
EOM Pharmaceuticals Holdings, Inc. announced that it has received $0.75 million in funding	22-09-11	CI
EOM Pharmaceuticals Holdings, Inc. announced a financing transaction	22-08-25	CI
EOM Pharmaceuticals Holdings, Inc. has filed an IPO in the amount of $25 million.	22-06-24	CI
ImmunoCellular Therapeutics, Ltd. Auditor Raises 'Going Concern' Doubt	22-06-23	CI
ImmunoCellular Therapeutics, Ltd. Auditor Raises 'Going Concern' Doubt	22-02-09	CI
EOM Pharmaceuticals, Inc. acquired ImmunoCellular Therapeutics, Ltd. in a reverse merger transaction.	21-12-01	CI
ImmunoCellular Therapeutics, Ltd.(AMEX:IMUC) dropped from S&P TMI Index	18-10-18	CI
ImmunoCellular Therapeutics, Ltd. Announces Executive Changes, Effective October 15, 2018	18-10-15	CI
ImmunoCellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	18-08-16	CI
ImmunoCellular Therapeutics Is Considering Strategic Alternatives	18-08-13	CI
ImmunoCellular Therapeutics, Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	18-05-14	CI
ImmunoCellular Therapeutics, Ltd. Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program	18-04-12	CI
Transcript : ImmunoCellular Therapeutics, Ltd., Q4 2017 Earnings Call, Mar 13, 2018	18-03-13
ImmunoCellular Therapeutics, Ltd. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	18-03-13	CI
ImmunoCellular Considers Strategic Alternatives	18-02-22	CI
ImmunoCellular Therapeutics, Ltd. Achieves Stem-to-T-Cell Research Immuno-Oncology Program	17-12-13	CI
Transcript : ImmunoCellular Therapeutics, Ltd., Q3 2017 Earnings Call, Nov 21, 2017	17-11-21
ImmunoCellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	17-11-21	CI
Certain Common Stock of ImmunoCellular Therapeutics, Ltd. are subject to a Lock-Up Agreement Ending on 16-OCT-2017.	17-10-15	CI
Certain Options of ImmunoCellular Therapeutics, Ltd. are subject to a Lock-Up Agreement Ending on 16-OCT-2017.	17-10-15	CI
Certain Restricted Stock Units of ImmunoCellular Therapeutics, Ltd. are subject to a Lock-Up Agreement Ending on 16-OCT-2017.	17-10-15	CI

Chart ImmunoCellular Therapeutics Ltd

Duration

Period

More charts

Company Profile

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.

Sector

More about the company